恶性脑膜瘤:一项国际多中心回顾性研究
该国际多中心回顾性研究纳入1989至2017年间6家机构治疗的178例恶性脑膜瘤患者,回顾分析病理报告与临床资料。中位随访4.5年,中位总生存2.9年(95%CI 2.4–4.5),多因素分析显示年龄<65岁、既往良性或非典型脑膜瘤手术史、切除完整性和辅助放疗为独立预后因素。
要点
- 178例恶性脑膜瘤患者中位总生存2.9年(95%CI 2.4–4.5),1年、5年、10年生存率分别为77.7%、40%和27.9%。
- 多因素分析显示年龄<65岁(HR=0.44)、完整切除(HR=0.51)和辅助放疗(HR=0.64)与生存改善相关。
- 既往良性或非典型脑膜瘤手术史与生存恶化相关(HR=1.9),即使积极治疗局部控制仍难以实现。
核心结论
- 该大样本系列研究证实恶性脑膜瘤预后差,治疗仍具挑战性。
- 年龄<65岁的原发性恶性脑膜瘤患者经完整切除和术后放疗后可能生存更长。
- 即使采用积极治疗,局部控制仍难以实现。
研究设计与样本
- 国际多中心回顾性研究,回顾性分析1989至2017年间6家国际机构治疗的178例恶性脑膜瘤患者的病理报告与临床资料。
- 76例(42.7%)有既往I级或II级脑膜瘤病史,患者共接受380次手术切除,72.5%接受放疗,中位随访4.5年。
主要发现
- 数据收集时111例(63.4%)已死亡,仅23例(13.7%)在最近一次影像检查时无残留肿瘤且存活。
- 中位总生存2.9年(95%CI 2.4–4.5);1年、5年、10年总生存率分别为77.7%(95%CI 71.6–84.3)、40%(95%CI 32.7–49)和27.9%(95%CI 20.9–37.3)。
- 多因素分析中,恶性脑膜瘤手术时年龄<65岁(HR=0.44,95%CI 0.29–0.67,P<.001)、既往良性或非典型脑膜瘤手术史(HR=1.9,95%CI 1.23–2.92,P=.004)、切除完整性(HR=0.51,95%CI 0.34–0.78,P=.002)和辅助放疗(HR=0.64,95%CI 0.42–0.98,P=.039)为生存的独立预后因素。
临床怎么用
- 作者认为年龄<65岁的原发性恶性脑膜瘤患者经完整切除和术后放疗后可能生存更长。
- 作者指出即使采用积极治疗,局部控制仍难以实现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In contrast to benign meningiomas, malignant meningiomas (MM) are rare and associated with an unfavourable prognosis. Reports on MM concern fairly small cohorts, often comprising less than 30 cases. OBJECTIVE: To describe the outcome MM and identify factors that may influence survival. METHODS: Pathology reports and clinical data of 178 patients treated between 1989 and 2017 for a MM at 6 different international institutions were retrospectively reviewed. Seventy-six patients (42.7%) had a previous history of grade I or grade II meningioma. The patients underwent a total of 380 surgical resections and 72.5% received radiotherapy. Median follow-up was 4.5 yr. RESULTS: At data collection, 111 patients were deceased (63.4%) and only 23 patients (13.7%) were alive without any residual tumor on the most recent scan. Median overall survival was 2.9 yr, 95% confidence interval [CI; 2.4, 4.5]. Overall survival rates at 1, 5, and 10 yr, respectively, were: 77.7%, 95% CI [71.6, 84.3], 40%, 95% CI [32.7, 49], and 27.9%, 95% CI [20.9, 37.3]. In the multivariable analysis, age at MM surgery <65 yr (hazard ratio [HR] = 0.44, 95% CI [0.29, 0.67], P < .001), previous benign or atypical meningioma surgery (HR = 1.9, 95% CI [1.23, 2.92], P = .004), completeness of resection (HR = 0.51, 95% CI [0.34, 0.78], P = .002), and adjuvant radiotherapy (HR = 0.64, 95% CI [0.42, 0.98], P = .039) were established as independent prognostic factors for survival. CONCLUSION: This large series confirms the poor prognosis associated with MM, the treatment of which remains challenging. Patients under 65-yr-old with primary MM may live longer after complete resection and postoperative radiotherapy. Even with aggressive treatments, local control remains difficult to achieve.
引用
- Champeaux C, Jecko V, Houston D, et al. Malignant Meningioma: An International Multicentre Retrospective Study. Neurosurgery. 2019. PMID: 30566646. doi:10.1093/neuros/nyy610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。